Neuroendocrine differentiation in gastric cancer: Epidemiological insights and therapeutic implications

#4003

Introduction: Gastric cancer (GC) with neuroendocrine differentiation (NED) represents a significant yet understudied subset, accounting for 10-40% of cases. The absence of tailored clinical guidelines highlights the urgent need for specialized treatment approaches.

Aim(s): This study aims to understand the NED epidemiological traits and clinical impacts of NED treatments in GC.

Materials and methods: This study enrolled 149 GC pts and assessed NED status by immunohistochemistry (synaptophysin, chromogranin A, CD56) in surgical samples. Pts were categorized into NED-positive or -negative groups for analyses. The efficacy and safety of first-line (surufatinib + SOX + anti-PD-1 antibody) and second-line (surufatinib + anti-PD-1 antibody) therapies were further explored in 6 GC with NED pts.

Conference:

Presenting Author:

Authors: Huang Z, Wei J, Shen Y, Zhang J,

Keywords: Neuroendocrine Differentiation, Epidemiological, Treatment, Surufatinib,